tiprankstipranks
Altimmune Inc (GB:0A4C)
LSE:0A4C
UK Market
0A4C
Altimmune
RESEARCH TOOLSreports

Altimmune (0A4C) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0A4C Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Altimmune
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0A4C Stock 12 Month Forecast

Average Price Target

$19.50
▲(574.74% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $19.50 with a high forecast of $28.00 and a low forecast of $10.00. The average price target represents a 574.74% change from the last price of $2.89.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","8":"$8","15":"$15","22":"$22","29":"$29"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8,15,22,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.889,4.820615384615385,6.752230769230769,8.683846153846154,10.615461538461538,12.547076923076922,14.478692307692308,16.410307692307693,18.341923076923077,20.27353846153846,22.205153846153845,24.136769230769232,26.068384615384616,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.889,4.166769230769231,5.444538461538461,6.722307692307693,8.000076923076923,9.277846153846154,10.555615384615384,11.833384615384615,13.111153846153845,14.388923076923076,15.666692307692307,16.94446153846154,18.22223076923077,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.889,3.436,3.9829999999999997,4.529999999999999,5.077,5.6240000000000006,6.170999999999999,6.718,7.265000000000001,7.811999999999999,8.359,8.906,9.453,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.683,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.683,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.683,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.865,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.889,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.889,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$19.50Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on GB:0A4C
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$20
Buy
592.04%
Upside
Reiterated
08/17/26
Altimmune Maintained at Buy as Late-Stage Liver Programs Advance and $20 Price Target Remains Unchanged
Jefferies Analyst forecast on GB:0A4C
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$28
Buy
868.86%
Upside
Reiterated
08/13/26
Jefferies Keeps Their Buy Rating on Altimmune (ALT)
Barclays Analyst forecast on GB:0A4C
Eliana Merle
Barclays
Barclays
$20
Buy
592.04%
Upside
Reiterated
08/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (NASDAQ: STRO), Summit Therapeutics (NASDAQ: SMMT) and Altimmune (NASDAQ: ALT)
William Blair Analyst forecast on GB:0A4C
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Oscar Health (NYSE: OSCR), Altimmune (NASDAQ: ALT) and HCA Healthcare (NYSE: HCA)
Truist Financial Analyst forecast on GB:0A4C
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (NASDAQ: GOVX), Incyte (NASDAQ: INCY) and Altimmune (NASDAQ: ALT)
Leerink Partners Analyst forecast on GB:0A4C
Thomas Smith
Leerink Partners
Leerink Partners
$10
Buy
246.02%
Upside
Reiterated
07/28/26
Leerink remains bullish on Altimmune following 'positive' AUD trial resultsLeerink remains bullish on Altimmune following 'positive' AUD trial results
Citizens JMP Analyst forecast on GB:0A4C
Jonathan Wolleben
Citizens JMP
Citizens JMP
$14→$11
Buy
280.62%
Upside
Reiterated
05/14/26
Altimmune price target lowered to $11 from $14 at CitizensAltimmune price target lowered to $11 from $14 at Citizens
Goldman Sachs Analyst forecast on GB:0A4C
Corinne Johnson
Goldman Sachs
Goldman Sachs
$1→$2.5
Hold
-13.49%
Downside
Upgraded
04/24/26
Altimmune upgraded to Neutral from Sell at Goldman SachsAltimmune upgraded to Neutral from Sell at Goldman Sachs
B. Riley Securities Analyst forecast on GB:0A4C
William Wood
B. Riley Securities
B. Riley Securities
$18→$13
Buy
349.83%
Upside
Reiterated
03/06/26
Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Altimmune (NASDAQ: ALT) and Cormedix (NASDAQ: CRMD)
JonesTrading Analyst forecast on GB:0A4C
Boris Peaker
JonesTrading
JonesTrading
$7
Buy
142.21%
Upside
Initiated
02/13/26
Altimmune initiated with a Buy at Titan PartnersAltimmune initiated with a Buy at Titan Partners
Stifel Nicolaus Analyst forecast on GB:0A4C
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
12/19/25
Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on GB:0A4C
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$20
Buy
592.04%
Upside
Reiterated
08/17/26
Altimmune Maintained at Buy as Late-Stage Liver Programs Advance and $20 Price Target Remains Unchanged
Jefferies Analyst forecast on GB:0A4C
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$28
Buy
868.86%
Upside
Reiterated
08/13/26
Jefferies Keeps Their Buy Rating on Altimmune (ALT)
Barclays Analyst forecast on GB:0A4C
Eliana Merle
Barclays
Barclays
$20
Buy
592.04%
Upside
Reiterated
08/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (NASDAQ: STRO), Summit Therapeutics (NASDAQ: SMMT) and Altimmune (NASDAQ: ALT)
William Blair Analyst forecast on GB:0A4C
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Oscar Health (NYSE: OSCR), Altimmune (NASDAQ: ALT) and HCA Healthcare (NYSE: HCA)
Truist Financial Analyst forecast on GB:0A4C
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (NASDAQ: GOVX), Incyte (NASDAQ: INCY) and Altimmune (NASDAQ: ALT)
Leerink Partners Analyst forecast on GB:0A4C
Thomas Smith
Leerink Partners
Leerink Partners
$10
Buy
246.02%
Upside
Reiterated
07/28/26
Leerink remains bullish on Altimmune following 'positive' AUD trial resultsLeerink remains bullish on Altimmune following 'positive' AUD trial results
Citizens JMP Analyst forecast on GB:0A4C
Jonathan Wolleben
Citizens JMP
Citizens JMP
$14→$11
Buy
280.62%
Upside
Reiterated
05/14/26
Altimmune price target lowered to $11 from $14 at CitizensAltimmune price target lowered to $11 from $14 at Citizens
Goldman Sachs Analyst forecast on GB:0A4C
Corinne Johnson
Goldman Sachs
Goldman Sachs
$1→$2.5
Hold
-13.49%
Downside
Upgraded
04/24/26
Altimmune upgraded to Neutral from Sell at Goldman SachsAltimmune upgraded to Neutral from Sell at Goldman Sachs
B. Riley Securities Analyst forecast on GB:0A4C
William Wood
B. Riley Securities
B. Riley Securities
$18→$13
Buy
349.83%
Upside
Reiterated
03/06/26
Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Altimmune (NASDAQ: ALT) and Cormedix (NASDAQ: CRMD)
JonesTrading Analyst forecast on GB:0A4C
Boris Peaker
JonesTrading
JonesTrading
$7
Buy
142.21%
Upside
Initiated
02/13/26
Altimmune initiated with a Buy at Titan PartnersAltimmune initiated with a Buy at Titan Partners
Stifel Nicolaus Analyst forecast on GB:0A4C
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
12/19/25
Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Altimmune

3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
11/19 ratings generated profit
58%
Average Return
-3.42%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of -3.42% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
11/32 ratings generated profit
34%
Average Return
+6.30%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of +6.30% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
11/32 ratings generated profit
34%
Average Return
-22.70%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 34.38% of your transactions generating a profit, with an average return of -22.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A4C Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
5
8
6
9
8
Buy
0
2
2
3
1
Hold
2
3
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
13
10
14
11
In the current month, 0A4C has received 9 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0A4C average Analyst price target in the past 3 months is 19.50.
Each month's total comprises the sum of three months' worth of ratings.

0A4C Financial Forecast

0A4C Earnings Forecast

Next quarter’s earnings estimate for 0A4C is -$0.14 with a range of -$0.15 to -$0.12. The previous quarter’s EPS was -$0.12. 0A4C beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A4C has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0A4C is -$0.14 with a range of -$0.15 to -$0.12. The previous quarter’s EPS was -$0.12. 0A4C beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A4C has Performed in-line its overall industry.

0A4C Sales Forecast

Next quarter’s sales forecast for 0A4C is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. 0A4C beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A4C has Performed in-line its overall industry.
Next quarter’s sales forecast for 0A4C is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. 0A4C beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A4C has Performed in-line its overall industry.

0A4C Stock Forecast FAQ

What is GB:0A4C’s average 12-month price target, according to analysts?
Based on analyst ratings, Altimmune Inc’s 12-month average price target is 19.50.
    What is GB:0A4C’s upside potential, based on the analysts’ average price target?
    Altimmune Inc has 574.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Altimmune Inc a Buy, Sell or Hold?
          Altimmune Inc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Altimmune Inc’s share price target?
            The average share price target for Altimmune Inc is 19.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $28.00 ,and the lowest forecast is $10.00. The average share price target represents 574.74% Increase from the current price of $2.89.
              What do analysts say about Altimmune Inc?
              Altimmune Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Altimmune Inc?
                To buy shares of GB:0A4C, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.